Mr. Chris Dallin reports

ASEP MEDICAL HOLDINGS ANNOUNCES REVOCATION OF FAILURE-TO-FILE CEASE TRADE ORDER

ASEP Medical Holdings Inc.'s principal regulator, the British Columbia Securities Commission (BCSC), has issued a revocation order lifting the failure-to-file cease trade order (FFCTO) previously imposed on the company.

The FFCTO was originally issued on May 6, 2025, as a result of the company's delay in filing its annual audited financial statements for the fiscal year ended Dec. 31, 2024, along with the accompanying management discussion and analysis and related certifications within the prescribed time period under applicable securities regulations.

During the period in which the FFCTO was in effect, the company continued to operate its core business activities; however, trading in the company's securities was temporarily restricted. The revocation restores normal trading activity.

ASEP Medical remains committed to maintaining strong corporate governance practices and timely financial reporting. With the FFCTO now revoked pursuant to National Policy 11-207, Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions, the company will continue to advance its strategic initiatives, including the further development and commercialization of its sepsis diagnostic (SepsetER) and anti-biofilm peptide technology platforms.

The company appreciates the patience and continued support of its shareholders and stakeholders throughout this process.

About ASEP Medical Holdings Inc.

ASEP Medical is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E.W. Hancock, one of the world's foremost microbiologists and the chief executive officer of Asep. Asep holds a controlling interest in two private subsidiary companies -- Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

We seek Safe Harbor.